Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Seema A Bhat, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Nyla A Heerema, PhD, Lynne V. Abruzzo, MD PhD, Cecelia Miller, PhD, Jennifer Zvosec, CCRP, Kasturi Ganesh-Barki, MBBS, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-138612

Published: 2020

Journal Articles

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Daniel Goldstein, MD, Kyle A. Beckwith, MDPhD, Cecelia Miller, PhD, Ying Huang, MS, MA, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, David A. Bond, MD, John C. Byrd, MD, Michael R. Grever, MD, Nyla A Heerema, PhD, Kerry A. Rogers, MD, Amy S. Ruppert, PhD, Jennifer A. Woyach, MD, Adam S. Kittai, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136714

Published: 2020

Journal Articles

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, Corinne Hoffman, MS, CNP, Kami J. Maddocks, MD, Gerard Lozanski, MD, Adam S. Kittai, MD, Mollie E. Moran, Mark Reid, CNP, Jennifer A. Woyach, MD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137655

Published: 2020

Journal Articles

Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events

Dan Jones, MD PhD, Huolin Tu, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Xiaokang Pan, PhD, Susan Long, Brianna Sisson, Sean Caruthers, Peng Ru, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Lynne V. Abruzzo, MD PhD, Weiqiang Zhao, MD PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2018-99-116293

Published: 2018

Journal Articles

Aberrant Methylation and Decreased Expression of NRIP1 in IGHV -Unmutated CLL

Madelyn Gerber, PhD, Yali Zhu, PhD, Yue-Zhong Wu, MAS, Brian Giacopelli, BS, Kevin Coombes, PhD, Christopher C Oakes, PhD, Lynne V. Abruzzo, MD PhD

Blood (2016) 128 (22): 1527.

https://doi.org/10.1182/blood.V128.22.1527.1527

Published: 2016

Journal Articles

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Blood (2016) 128 (22): 3198.

https://doi.org/10.1182/blood.V128.22.3198.3198

Published: 2016

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

Journal Articles

MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS

Piyanuch Kongtim, MD, Uday R Popat, MD, Marcos de Lima, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Juliane Chen, Gabriela Rondon, MD, Lynne V. Abruzzo, MD, PhD, Stefan O. Ciurea, MD, Elizabeth J Shpall, MD, Richard E Champlin, MD, Betul Oran, MD

Blood (2013) 122 (21): 3340.

https://doi.org/10.1182/blood.V122.21.3340.3340

Published: 2013

Journal Articles

Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients

Deborah M Stephens, DO, Amy Stark, MAS, William G. Wierda, MD, PhD, Jeffrey A. Jones, MD, MPH, Jennifer A. Woyach, MD, Kami Maddocks, Samantha M. Jaglowski, MD, MPH, Leslie A Andritsos, MD, Joseph M. M. Flynn, DO, MPH, Michael R. Grever, MD, Gerard Lozanski, MD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, Susan O'Brien, MD, Michael J. Keating, MD, Natarajan Muthusamy, DVM, Ph.D, Lynne V. Abruzzo, MD, PhD, Nyla A. Heerema, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 4128.

https://doi.org/10.1182/blood.V122.21.4128.4128

Published: 2013

Journal Articles

Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS

Betul Oran, MD, Piyanuch Kongtim, MD, Marcos de Lima, MD, Uday R Popat, MD, Guillermo Garcia-Manero, Elias J. Jabbour, MD, Lynne V. Abruzzo, MD, PhD, Julianne Chen, Gabriela Rondon, MD, Borje S. Andersson, MD, PhD, Amin Alousi, MD, Stefan O. Ciurea, MD, Elizabeth J Shpall, MD, Richard E Champlin, MD

Blood (2013) 122 (21): 305.

https://doi.org/10.1182/blood.V122.21.305.305

Published: 2013

Journal Articles

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Maro Ohanian, DO, Mona Lisa Alattar, MD, Zeev Estrov, MD, PhD, Alfonso Quintas-Cardama, MD, John T Manning, MD, Farhad Ravandi, MD, Lynne V. Abruzzo, MD, PhD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 1463.

https://doi.org/10.1182/blood.V120.21.1463.1463

Published: 2012

Journal Articles

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Susan O'Brien, M.D., Stefan Faderl, MD, Rajyalakshmi Luthra, Ph.D., William G. Wierda, MD, Ph.D., Alessandra Ferrajoli, Sherry A. Pierce, RN, BS, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2562.

https://doi.org/10.1182/blood.V120.21.2562.2562

Published: 2012

Journal Articles

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

LM Poon, Patricia S Fox, MS, Barry I. Samuels, MD, Susan O'Brien, M.D., Alessandra Ferrajoli, M.D., Michael J. Keating, MD, Elias J. Jabbour, MD, Yvonne Hsu, Lynne V. Abruzzo, MD, PhD, Richard E. Champlin, Roland Bassett, Issa F. Khouri, MD

Blood (2012) 120 (21): 1977.

https://doi.org/10.1182/blood.V120.21.1977.1977

Published: 2012

Journal Articles

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Aziz Nazha, Hagop M. Kantarjian, MD, Preetesh Jain, MD, DM, PhD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, M.D., Rajyalakshmi Luthra, PhD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3757.

https://doi.org/10.1182/blood.V120.21.3757.3757

Published: 2012

Journal Articles

Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12

Paolo Strati, MD, Lynne V. Abruzzo, MD, PhD, William Wierda, MD, PhD, Susan Lerner, MS, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, M.D., Michael J. Keating, MD

Blood (2012) 120 (21): 3907.

https://doi.org/10.1182/blood.V120.21.3907.3907

Published: 2012

Journal Articles

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Preetesh Jain, MD, DM, PhD, Long Xuan Trinh, Ohad Benjamini, MD, Susan Lerner, MS, Xuemei Wang, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Zeev Estrov, MD, PhD, William G. Wierda, MD, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Lynne V. Abruzzo, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 2890.

https://doi.org/10.1182/blood.V120.21.2890.2890

Published: 2012

Journal Articles

Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),

Elias Jabbour, Hagop M. Kantarjian, Xuemei Wang, MS, Lynne V. Abruzzo, MD, PhD, A Megan Cornelison, Susan O'Brien, MD, Farhad Ravandi, MD, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Jorge E. Cortes, Guillermo Garcia-Manero

Blood (2011) 118 (21): 3802.

https://doi.org/10.1182/blood.V118.21.3802.3802

Published: 2011

Journal Articles

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Lisa Zipp, MS, Rima M Saliba, Ph.D., Rosamar Valverde, Grace-Julia Okoroji, Martin Korbling, MD, Barry I Samuels, MD, Lynne V. Abruzzo, MD, PhD, Amin M Alousi, MD, Borje S Andersson, MD, PhD, Chitra M Hosing, MD, Bill Erwin, MS, Paolo Anderlini, MD, Uday R Popat, MD, Partow Kebriaei, Homer A Macapinlac, MD, Richard Champlin, MD, Issa F. Khouri, MD

Blood (2011) 118 (21): 2005.

https://doi.org/10.1182/blood.V118.21.2005.2005

Published: 2011

Journal Articles

Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion,

Yvonne Hsu, Rima M Saliba, PhD, Grace-Julia Okoroji, Susan o'Brien, Alessandra Ferrajoli, MD, Lynne V. Abruzzo, MD, PhD, Richard Champlin, MD, Michael J Keating, MD, Issa F. Khouri, MD

Blood (2011) 118 (21): 4123.

https://doi.org/10.1182/blood.V118.21.4123.4123

Published: 2011

Journal Articles

Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis

Liunan Li, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Stefan Faderl, MD, Tapan Kadia, MD, Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, William G. Wierda, MD, PhD, Lynne V. Abruzzo, MD, PhD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2010) 116 (21): 2941.

https://doi.org/10.1182/blood.V116.21.2941.2941

Published: 2010

NARROW

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events

Aberrant Methylation and Decreased Expression of NRIP1 in IGHV -Unmutated CLL

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS

Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients

Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion,

Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only